Elanco Animal Health lifts earnings outlook on surge in tick‑related demand

Elanco Animal Health announced an upward revision of its 2026 revenue forecast, now expecting $5.09‑$5.14 billion, and raised its innovation‑revenue target to $1.25 billion. The company reported a 12% year‑over‑year increase in pet‑health revenue for Q2 2026, driven by higher volumes and modest price gains, and highlighted a new dermatology product that captured up to 40% market share in key European markets. Elanco attributed the stronger demand to a noticeable rise in tick bites, prompting pet owners to invest more in preventive treatments. The earnings lift was echoed across the animal‑health sector, with peers such as Virbac, Boehringer Ingelheim, ADM and Pet Service Holding also posting solid Q2 and H1 results despite broader market pressures.